NASDAQ:AGLEAeglea Bio Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aeglea Bio Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.86 +0.85 (+21.20 %) (As of 04/7/2020 04:19 AM ET) Add Compare Share Today's Range$4.23Now: $4.86▼$4.9150-Day Range$3.51MA: $5.80▼$8.2252-Week Range$3.50Now: $4.86▼$9.10Volume96,800 shsAverage Volume64,250 shsMarket Capitalization$141.35 millionP/E RatioN/ADividend YieldN/ABeta1.38 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB4104, a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocysteine; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAeglea Bio Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Aeglea Bio Therapeutics has a potential upside of 290.9% from its current price of $4.86.Amount of Analyst CoverageAeglea Bio Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAeglea Bio Therapeutics has received 230 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAeglea Bio Therapeutics has received 191 “underperform” votes. (Add your “underperform” vote.)Community SentimentAeglea Bio Therapeutics has received 54.63% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote “Outperform” if you believe AGLE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAeglea Bio Therapeutics does not currently pay a dividend.Dividend GrowthAeglea Bio Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeglea Bio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.60% of the stock of Aeglea Bio Therapeutics is held by insiders.Percentage Held by Institutions70.90% of the stock of Aeglea Bio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aeglea Bio Therapeutics are expected to decrease by -5.49% in the coming year, from ($2.73) to ($2.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeglea Bio Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeglea Bio Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeglea Bio Therapeutics has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGLE Previous Symbol CUSIPN/A CIK1636282 Webhttp://www.aegleabio.com/ Phone512-942-2935Debt Debt-to-Equity Ratio0.08 Current Ratio4.06 Quick Ratio4.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.89 million Price / Sales36.34 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book2.35Profitability EPS (Most Recent Fiscal Year)($2.45) Net Income$-78,250,000.00 Net MarginsN/A Return on Equity-87.98% Return on Assets-72.91%Miscellaneous Employees61 Outstanding Shares29,085,000Market Cap$141.35 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive AGLE News and Ratings via Email Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AGLE Rates by TradingView Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions How has Aeglea Bio Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Aeglea Bio Therapeutics' stock was trading at $5.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AGLE shares have decreased by 9.7% and is now trading at $4.86. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aeglea Bio Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aeglea Bio Therapeutics. When is Aeglea Bio Therapeutics' next earnings date? Aeglea Bio Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Aeglea Bio Therapeutics. How were Aeglea Bio Therapeutics' earnings last quarter? Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) issued its earnings results on Monday, February, 24th. The biotechnology company reported ($0.65) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.67) by $0.02. View Aeglea Bio Therapeutics' earnings history. What price target have analysts set for AGLE? 2 analysts have issued 1-year target prices for Aeglea Bio Therapeutics' stock. Their forecasts range from $14.00 to $24.00. On average, they anticipate Aeglea Bio Therapeutics' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 290.9% from the stock's current price. View analysts' price targets for Aeglea Bio Therapeutics. What are Wall Street analysts saying about Aeglea Bio Therapeutics stock? Here are some recent quotes from research analysts about Aeglea Bio Therapeutics stock: 1. According to Zacks Investment Research, "Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. " (1/8/2020) 2. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for pegzilarginase in ARG1-D and our year end fully diluted net cash estimate of $2.55/share to arrive at our price target. We use the net present value of our revenue forecast through 2028, apply a 50% POS of pegzilarginase in 4x price/sales multiple for ARG1-D to arrive at a value of $4.40/share. We use a 20% discount rate for the NPV of the pipeline as it is within the typical range of 15-25% for products in development." (6/3/2019) Has Aeglea Bio Therapeutics been receiving favorable news coverage? News coverage about AGLE stock has trended very negative recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aeglea Bio Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAeglea Bio Therapeutics. Are investors shorting Aeglea Bio Therapeutics? Aeglea Bio Therapeutics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 292,500 shares, an increase of 40.9% from the February 27th total of 207,600 shares. Based on an average daily trading volume, of 61,700 shares, the short-interest ratio is currently 4.7 days. Approximately 1.2% of the company's stock are sold short. View Aeglea Bio Therapeutics' Current Options Chain. Who are some of Aeglea Bio Therapeutics' key competitors? Some companies that are related to Aeglea Bio Therapeutics include Clovis Oncology (CLVS), Sinovac Biotech (SVA), DiaMedica Therapeutics (DMCAF), Verastem (VSTM), RAPT Therapeutics (RAPT), Emisphere Technologies (EMIS), Morphic (MORF), Prothena (PRTA), Urogen Pharma (URGN), AnaptysBio (ANAB), Avedro (AVDR), Xenon Pharmaceuticals (XENE), INDIVIOR PLC/S (INVVY), Neoleukin Therapeutics (NLTX) and Catalyst Pharmaceuticals (CPRX). What other stocks do shareholders of Aeglea Bio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea Bio Therapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Kura Oncology (KURA), AcelRx Pharmaceuticals (ACRX), Aduro BioTech (ADRO), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), ZIOPHARM Oncology (ZIOP) and Epizyme (EPZM). Who are Aeglea Bio Therapeutics' key executives? Aeglea Bio Therapeutics' management team includes the following people: Dr. Anthony G. Quinn M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 57)Mr. Charles N. York II, CFO & VP (Age 42)Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 53)Dr. Leslie Sloan Ph.D., Chief Operating Officer (Age 48)Mr. Eugene Sackett, VP of HR When did Aeglea Bio Therapeutics IPO? (AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager. What is Aeglea Bio Therapeutics' stock symbol? Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE." How do I buy shares of Aeglea Bio Therapeutics? Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aeglea Bio Therapeutics' stock price today? One share of AGLE stock can currently be purchased for approximately $4.86. How big of a company is Aeglea Bio Therapeutics? Aeglea Bio Therapeutics has a market capitalization of $141.35 million and generates $3.89 million in revenue each year. The biotechnology company earns $-78,250,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. Aeglea Bio Therapeutics employs 61 workers across the globe. View additional information about Aeglea Bio Therapeutics. What is Aeglea Bio Therapeutics' official website? The official website for Aeglea Bio Therapeutics is http://www.aegleabio.com/. How can I contact Aeglea Bio Therapeutics? Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: How to Trade Using Analysts Ratings
